TD Cowen still sees shares of Novo Nordisk adding 6% from here.
Get this delivered to your inbox, and more info about our products and services.
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its…
Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
The bank downgraded the Danish pharmaceutical giant to neutral from buy and decreased its price target.
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate…
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S.…
Eli Lilly's stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its…
